Revance announces leadership transition
The move follows Crown Laboratories' acquisition earlier this year of Revance Therapeutics and a rebranding initiative.
Revance, a fast-growing global leader in aesthetics and skincare, has announced a leadership transition to support the company’s next chapter of growth and innovation, as it builds toward becoming the most dynamic, science-backed, operationally disciplined, and customer-focused aesthetics and skincare company in the industry.
Jeff Bedard, who founded the company 25 years ago as Crown Laboratories in Johnson City with a vision to revolutionize skincare, will transition from Founder and Chief Executive Officer (CEO) to Founder and Executive Chairman of the Board. Nadeem Moiz, President, Chief Operating Officer, and Chief Financial Officer, will become CEO effective October 1, 2025.
As Executive Chairman, Bedard will remain actively involved, working closely with Moiz to ensure continuity in Revance’s customer and patient-first approach, while supporting long-term strategy and mentoring the leadership team. In their new roles, Moiz will continue to report to Bedard.
The long-term succession plan is a natural next step in the evolution of the newly combined company. Earlier this year, Crown Laboratories acquired Revance Therapeutics, creating a comprehensive portfolio that spans from everyday skincare needs to advanced aesthetics treatments. In March, the company announced it would begin operating under the name Revance, bringing together award-winning consumer brands like PanOxyl®, Blue Lizard® and StriVectin®, along with innovative aesthetics solutions including DAXXIFY® (DaxibotulinumtoxinA-lanm), the RHA® Collection by Teoxane SA, and SkinPen®.
Like what you've read?
Forward to a friend!